## Summary

The paper proposes xImagand-DKI, a multi-view conditional diffusion model that simultaneously generates 9 pharmacokinetic (PK) properties and 3 drug-target interaction (DTI) values from SMILES and protein sequence inputs. To improve generation quality, the model infuses additional domain knowledge from Gene Ontology (via PO2Vec) and molecular fingerprints (via FPFormer). The authors claim xImagand-DKI addresses data overlap sparsity in drug discovery datasets by generating synthetic data that closely matches real univariate/bivariate distributions and can improve downstream machine learning efficiency (MLE).

## Strengths

- **Addresses a relevant and practical problem**: Data overlap sparsity across PK and DTI datasets is a genuine obstacle in computational drug discovery. The motivation to generate synthetic data to fill these gaps is well-founded and practically important.
- **Unified generation of PK and DTI in a single model**: Unlike prior work (Syngand, cGAN) that targets only PK properties, xImagand-DKI jointly generates both PK and DTI outputs, which is a step toward integrated preclinical prediction.
- **Multi-view domain knowledge infusion**: Incorporating Gene Ontology embeddings (PO2Vec) and multiple molecular fingerprints (via FPFormer) alongside standard SMILES/protein encoders is a reasonable strategy to enrich representations and is a clear differentiator from standard sequence-only models.
- **Comprehensive evaluation dimensions**: The paper evaluates synthetic data through univariate (Hellinger distance), bivariate (differential pairwise correlations), and downstream task (MLE) metrics across 9 PK and 3 DTI datasets, providing a multi-faceted view of quality.

## Weaknesses

### Major

- **Insufficient methodological detail, compromising reproducibility**: The fusion mechanism for the four input views (ProtBERT, PO2Vec, DeBERTa, FPFormer) is not described. The paper states that "1D patches are computed from the classifier-free guidance of SMILES and protein embeddings" but does not specify how the PO2Vec and FPFormer embeddings are integrated, how many layers/heads the transformer uses, or the exact loss masking procedure. Training hyperparameters are deferred to a missing appendix. Without these details, the method cannot be faithfully reproduced.
- **MLE evaluation protocol is unclear and results appear anomalous**: Table 3 reports that models trained on synthetic data (cGAN, Imagand, Ours) achieve *vastly* lower MSE (e.g., C2: 0.06 vs. 0.63) and better R² than a model trained on real data, yet the real-trained model has a negative R² (e.g., C2: –3.2). This suggests the real training split may be extremely difficult or the evaluation protocol is flawed (e.g., maybe synthetic data is used for *augmentation* rather than pure replacement, or the test set distribution differs). The paper says "synthetic augmented dataset can outperform real data" but never clarifies whether the synthetic data is used alone or combined with real data. This ambiguity undermines the main empirical claim.
- **Domain knowledge infusion does not consistently improve univariate quality**: In Table 2, the "No DKI" ablation achieves a better Hellinger distance than "Ours" on Caco-2 (0.12 vs. 0.13) and CIH (0.13 vs. 0.15). The paper does not discuss these counterexamples or explain when DKI helps versus hurts. The overall improvement from DKI is marginal, and the ablation results weaken the paper's central claim about the benefit of multi-view infusion.
- **Incomplete bivariate analysis for DTI properties**: Figure 4 and the DPC analysis include only one DTI property (Ki). The other two DTI targets (Kd and IC50) are absent from the visual bivariate comparison, making it unclear whether the model preserves correlations involving those outputs.

### Minor

- **Weak baselines**: The primary baselines are cGAN (2014) and the authors' own prior works (Syngand, Imagand). There is no comparison to other recent generative models (e.g., diffusion-based property generators, VAEs, or molecule-conditioned GANs) that could handle the same task.
- **Overclaiming**: Describing a model covering 12 properties as a "foundational model" is a stretch given the scale and scope of actual foundation models in biology (e.g., AlphaFold, ESM). The claim that xImagand-DKI represents a "major step towards building a new class of foundational models" is not supported by the evidence.
- **No statistical significance measures**: Tables report averages over 30 trials but no confidence intervals, standard deviations, or p-values, making it difficult to assess whether observed differences are meaningful.

### Trivial

- The open-source code link is listed as "TBD", preventing immediate verification.

## Nice-to-Haves

- A concrete example of gap-filling (e.g., a molecule with only PK data for which xImagand-DKI generates DTI values) would help illustrate the practical utility.
- Additional baselines (e.g., VAE, Score-based generative model) would strengthen the empirical comparison.
- Provide confidence intervals or error bars for all reported metrics.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. Clarify the MLE protocol: specify whether synthetic data is used alone, as augmentation, or only for training, and explain why the real-trained model achieves such poor performance (e.g., small training sets, high noise). Provide full details in the main paper.
2. Describe the fusion of the four input views in concrete terms (e.g., concatenation, cross-attention, or separate encoders). Provide a clear equation or diagram.
3. Include the missing training hyperparameters (architecture, learning rate, diffusion steps, etc.) in the main text if the appendix is stripped.
4. Discuss the cases where DKI hurts performance (Caco-2, CIH) and analyze whether the infusion introduces noise or redundancy.
5. Report results for all three DTI properties in the bivariate analysis, not just Ki.

## Score and Decision

Score: 3.5

Decision: Reject

MY FINAL SCORE: <score>3.5</score>  
MY FINAL DECISION: <decision>Reject</decision>